An update on antiviral antibody-based biopharmaceuticals.
Int Immunopharmacol
; 86: 106760, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: covidwho-634138
ABSTRACT
Due to the vastness of the science virology, it is no longer an offshoot solely of the microbiology. Viruses have become as the causative agents of major epidemics throughout history. Many therapeutic strategies have been used for these microorganisms, and in this way the recognizing of potential targets of viruses is of particular importance for success. For decades, antibodies and antibody fragments have occupied a significant body of the treatment approaches against infectious diseases. Because of their high affinity, they can be designed and engineered against a variety of purposes, mainly since antibody fragments such as scFv, nanobody, diabody, and bispecific antibody have emerged owing to their small size and interesting properties. In this review, we have discussed the antibody discovery and molecular and biological design of antibody fragments as inspiring therapeutic and diagnostic agents against viral targets.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Productos Biológicos
/
Infecciones por Coronavirus
/
Betacoronavirus
/
Anticuerpos Antivirales
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Animales
/
Humanos
Idioma:
Inglés
Revista:
Int Immunopharmacol
Asunto de la revista:
Alergia e Inmunología
/
Farmacología
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
J.intimp.2020.106760
Similares
MEDLINE
...
LILACS
LIS